Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vancomycin prophylaxis to prevent Clostridioides difficile infection after allogeneic hematopoietic stem cell transplantation
2021-003835-28Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Oral vancomycin prophylaxis with Placebo (2 arms). Primary endpoint: Clostridioides difficile infection from inclusion to discharge or end of vancomycin treatment. Started Dec 2021; status: active.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2021-003835-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003835-28.